1 / 15

Aarkstore - Wounds - Pipeline Review, H2 2014

“Wounds - Pipeline Review, H2 2014” report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.

addyparker2350
Télécharger la présentation

Aarkstore - Wounds - Pipeline Review, H2 2014

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Category : Pharmaceuticals & Healthcare Wounds - Pipeline Review, H2 2014 Browse Complete Report - http://www.aarkstore.com/pharmaceuticals-healthcare/63080/wounds-pipeline-review

  2. Wounds - Pipeline Review, H2 2014

  3. Summary Global Markets Direct’s, ‘Wounds - Pipeline Review, H2 2014’, provides an overview of the Wounds’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

  4. Summary Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  5. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects- The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages- A detailed assessment of monotherapy and combination therapy pipeline projects- Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type- Latest news and deals relating related to pipeline products

  6. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Develop strategic initiatives by understanding the focus areas of leading companies- Identify and understand important and diverse types of therapeutics under development for Wounds- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline- Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

  7. Table of Content List of Tables 7List of Figures 9Introduction 10Global Markets Direct Report Coverage 10Wounds Overview 11Therapeutics Development 12Pipeline Products for Wounds - Overview 12Pipeline Products for Wounds - Comparative Analysis 13Wounds - Therapeutics under Development by Companies 14Wounds - Therapeutics under Investigation by Universities/Institutes 20Wounds - Pipeline Products Glance 22Late Stage Products 22Clinical Stage Products 23Early Stage Products 24Unknown Stage Products 25Wounds - Products under Development by Companies 26

  8. Table of Content Wounds - Products under Investigation by Universities/Institutes 31Wounds - Companies Involved in Therapeutics Development 33Advancell 33Aerpio Therapeutics, Inc. 34AlgiPharma AS 35AndroScience Corporation 36AnGes MG, Inc. 37APEIRON Biologics AG 38Apricus Biosciences, Inc. 39Aridis Pharmaceuticals LLC 40Beech Tree Labs, Inc. 41Bio3 Research S.r.l 42Biotec Pharmacon ASA 43Birken AG 44Blueberry Therapeutics Ltd 45

  9. List Of Tables Number of Products under Development for Wounds, H2 2014 18Number of Products under Development for Wounds - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 21Number of Products under Development by Companies, H2 2014 (Contd..1) 22Number of Products under Development by Companies, H2 2014 (Contd..2) 23Number of Products under Development by Companies, H2 2014 (Contd..3) 24Number of Products under Development by Companies, H2 2014 (Contd..4) 25Number of Products under Investigation by Universities/Institutes, H2 2014 27Comparative Analysis by Late Stage Development, H2 2014 28Comparative Analysis by Clinical Stage Development, H2 2014 29Comparative Analysis by Early Stage Development, H2 2014 30Comparative Analysis by Unknown Stage Development, H2 2014 31

  10. List Of Tables Products under Development by Companies, H2 2014 32Products under Development by Companies, H2 2014 (Contd..1) 33Products under Development by Companies, H2 2014 (Contd..2) 34Products under Development by Companies, H2 2014 (Contd..3) 35Products under Development by Companies, H2 2014 (Contd..4) 36Products under Investigation by Universities/Institutes, H2 2014 37Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 38Wounds - Pipeline by Advancell, H2 2014 39Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2014 40Wounds - Pipeline by AlgiPharma AS, H2 2014 41Wounds - Pipeline by AndroScience Corporation, H2 2014 42Wounds - Pipeline by AnGes MG, Inc., H2 2014 43Wounds - Pipeline by APEIRON Biologics AG, H2 2014 44Wounds - Pipeline by Apricus Biosciences, Inc., H2 2014 45

  11. List of Figures Number of Products under Development for Wounds, H2 2014 18Number of Products under Development for Wounds - Comparative Analysis, H2 2014 19Number of Products under Development by Companies, H2 2014 20Number of Products under Investigation by Universities/Institutes, H2 2014 26Comparative Analysis by Clinical Stage Development, H2 2014 29Comparative Analysis by Early Stage Products, H2 2014 30Assessment by Monotherapy Products, H2 2014 93Number of Products by Top 10 Targets, H2 2014 94Number of Products by Stage and Top 10 Targets, H2 2014 94Number of Products by Top 10 Mechanism of Actions, H2 2014 97Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 97Number of Products by Top 10 Routes of Administration, H2 2014 100Number of Products by Stage and Top 10 Routes of Administration, H2 2014 101

  12. Related Reports • Global Neurosurgery Market 2015-2019 • BrainStorm Cell Therapeutics Inc. (BCLI) - Financial and Strategic SWOT Analysis Review • Ampio Pharmaceuticals, Inc. (AMPE) - Financial and Strategic SWOT Analysis Review • MiMedx Group, Inc (MDXG) - Financial and Strategic SWOT Analysis Review • Threshold Pharmaceuticals, Inc. (THLD) - Financial and Strategic SWOT Analysis Review

  13. Related Reports • MEI Pharma, Inc. (MEIP) - Financial and Strategic SWOT Analysis Review • Titan Pharmaceuticals, Inc. (TTNP) - Financial and Strategic SWOT Analysis Review • RedHill Biopharma Ltd. (RDHL) - Financial and Strategic SWOT Analysis Review • Pharmaceuticals & Healthcare Market Research Reports

  14. Wounds - Pipeline Review, H2 2014 Published: Oct 2014 | 246 Pages Wounds - Pipeline Review, H2 2014 report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications.  Price

  15. Contact Us Office Office No. - 809, 8th Floor,B-Wing, Mahaavir Icon, Plot No.- 89 & 90, Sector-15,CBD-Belapur, Navi Mumbai – 400614, Maharashtra, India. Telefax No: +91 22 4127 6660 24/7 Online Support: +91 9987295242 General Inquiries : +91 - 22 2756 4953 You Can Visit http://www.aarkstore.com OR Mail us at contact@aarkstore.com Blog : http://www.aarkstore.com/blog/ Conference : http://conference.aarkstore.com/ News : http://www.aarkstore.com/news

More Related